News Releases

April 16, 2019

Josephine Mauskopf has been awarded the Marilyn Dix Smith Leadership Award by ISPOR.  

April 9, 2019

Applied Health Economics for Public Health Practice and Research, has been published. Chapter 9, coauthored by Willings Botha,

February 18, 2019

Meet researcher Naoko Ronquest, Senior Director in our HE Modeling Program.

February 8, 2019

Research just published in Value in Health compares FDA and EMA labeling for evidence based on patient-reported outcomes (PROs) of new oncology treatments approved by both agencies.

February 6, 2019

Regulators and reimbursement authorities want to utilize real-world data more consistently to capture the real-world patient and clinician experience.

February 6, 2019

This paper describes study methods, challenges, and the study’s progress so far.

January 7, 2019

Research addressing concerns about the rising cost of health care in the United States

January 7, 2019

Reliance on statistical significance, and the related statistic, the P-value, is a drawback. Here are alternatives.

December 13, 2018

The RTI-HS Festive Cheer Score (FCS) is at its peak!

October 30, 2018

In 2014, a head-to-head clinical trial compared the 96-week efficacy and tolerability of three HIV multi-drug combinations commonly used as initial treatment for individuals with HIV-1 infection.

October 22, 2018

ISPOR Good Practices for Outcomes Research Provide Guidance for High-, Middle-, and Low-Income Countries

October 15, 2018

CADASIL, or cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, is a rare genetic disorder caused by mutations in the NOTCH3 gene. It is a neurological degenerative disorder leading to cognitive impairment and eventually vascular dementia.

September 22, 2018

Multiple myeloma (MM) is an incurable cancer of the bone marrow. It is the third-most-frequent blood cancer in the US, after lymphoma and leukemia. Several new therapies have recently been approved by the United States Food and Drug Administration (FDA) for treatment of MM, including daratumumab...

September 17, 2018

Patients with drug-resistant epilepsy (DRE) utilize more health care resources and face higher costs than patients who can control their condition with anti-epileptic drugs (AEDs). Despite the long-term proven effectiveness of vagus nerve stimulation (VNS), the treatment is currently...

August 20, 2018

Qualitative data on patients’ experiences and perspectives typically go uncollected in clinical trial settings. Yet patients’ treatment experiences offer complementary insights and context on topics such as disease management, treatment gaps, and previous treatments outside of those gathered in...

July 31, 2018

Often, drug manufacturers are faced with limited study data when developing therapies for rare diseases. To identify challenges in creating economic models, researchers at RTI Health Solutions coauthored a study that reviewed health technology assessment submissions for rare disease treatments...

July 20, 2018

Research on the impact of diabetes on quality of life often focuses on understanding the effect of specific interventions.

July 18, 2018

The PSA test is used to screen men for prostate cancer, however there is controversy around its poor sensitivity and specificity. It can lead to unnecessary biopsies and the overtreatment of low-grade cancers.

July 17, 2018

Communication of Pre-approval Information by Drug and Device Manufacturers to Payers in the US

June 28, 2018

It’s no longer business as usual. We are entering a new era of capturing patients’ voice in cancer drug development. It is critical to remain abreast of trends in the regulatory environment. Ari Gnanasakthy shares takeaways from FDA/ASCO workshop.

June 25, 2018

This new book serves as an essential reference for pharmacovigilance scientists and pharmacoepidemiologists searching for the appropriate study design to answer safety research questions in studies required by regulators. Two RTI Health Solutions (RTI-HS) researchers are contributors. 

June 22, 2018

Biopharmaceutical Innovation Has Significant Impact, According to Physicians Surveyed. A recent survey of U.S. physicians provides insight on their perceptions regarding the impact of medical innovation on outcome

June 12, 2018

Soft tissue sarcoma (STS) is a rare group of malignant tumors comprising more than 50 histologic subtypes that are derived from connective tissues and other cells of mesenchymal origin. They account for approximately 1% of all incident malignancies.

May 22, 2018

Understanding What Matters Most to Alzheimer's patients and their caregivers to help inform the drug development process.
The Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE) initiative is a first-of-its-kind collaboration among pharmaceutical companies, advocacy...

May 18, 2018

Research team members each have their own areas of expertise, which may not include experience with raw data.  They all need tools they can understand to help them assess the data.